Leaderboards/Antiplatelet Therapy and Cardiovascular Diseases

Antiplatelet Therapy and Cardiovascular Diseases

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Dominick Angiolillo Angiolillo
University of Florida
2
Nisha Khatiwada
Texas Tech University
3
Yanan Wang
Wenzhou Medical University
4
Obbina Abani
Unknown
5
Pedrum Mohammadi‐Shemirani
Takeda (United States)
6
Maria-Luisa Straßmeir
University Clinic of Traumatology
7
Michael Moster
University of Basel
8
Filippo Luca Gurgoglione
University of Parma
9
Niels M R van der Sangen
Amsterdam Neuroscience
10
Jeehoon Kang
Seoul National University Hospital

Papers

1
Potential Benefits and Risks Associated with the Use of Statins
Pharmaceutics|2024
89 cit.
2
Publication in Future Pharmacology (2024) [21 citations, W4404061296]
Future Pharmacology|2024
21 cit.
3
Publication in Cardiovascular revascularization medicine (2024) [18 citations, W4401059347]
Cardiovascular revascularization medicine|2024
18 cit.
4
Publication in The American Journal of Cardiology (2024) [14 citations, W4405430552]
The American Journal of Cardiology|2024
14 cit.
5
Self-adaptive covalent coating for vascular stents: Coordinated coagulation-inflammation regulation to support re-endothelialization for atherosclerosis control
Biomaterials|2025
10 cit.
6
Publication in The American Journal of Cardiology (2025) [9 citations, W4413149081]
The American Journal of Cardiology|2025
9 cit.
7
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet Infectious Diseases|2025
8 cit.
8
Publication in EClinicalMedicine (2025) [3 citations, W4407400500]
EClinicalMedicine|2025
3 cit.
9
Publication in European Heart Journal - Cardiovascular Pharmacotherapy (2025) [3 citations, W4409386874]
European Heart Journal - Cardiovascular Pharmacotherapy|2025
3 cit.
10
Publication in The Lancet (2026) [3 citations, W7142748965]
The Lancet|2026
3 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Xavier Rosselló
Spanish National Centre for Cardiovascular Research
2
Oliver Rasp
Friedrich-Alexander-Universität Erlangen-Nürnberg
3
Rick Andreae
National University of Ireland
4
Hiroki Uehara
Hokkaido University
5
Michelle O'Donoghue O'Donoghue
Brigham and Women's Hospital
6
Chuck Simonton
Johnson & Johnson (United States)
7
Prabhakara R. Nagareddy
University of Oklahoma Health Sciences Center
8
Naoko Kumagai
Tohoku University
9
Rifang Luo
Sichuan University
10
Alastair J.S. Webb
Imperial College London

Papers

1
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
JAMA Cardiology|2022
300 cit.
2
Antiplatelet therapy after percutaneous coronary intervention
EuroIntervention|2022
282 cit.
3
European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack
European Stroke Journal|2022
202 cit.
4
β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials
The Lancet|2025
70 cit.
5
Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines
European Heart Journal - Quality of Care and Clinical Outcomes|2023
54 cit.
6
Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial
Circulation Research|2024
32 cit.
7
Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial
European Heart Journal|2025
20 cit.
8
Effect of an intensive lifestyle intervention on the structural and functional substrate for atrial fibrillation in people with metabolic syndrome
European Journal of Preventive Cardiology|2023
17 cit.
9
The fragility index in randomized clinical trials supporting clinical practice guidelines for acute coronary syndrome: measuring robustness from a different perspective
European Heart Journal Acute Cardiovascular Care|2023
16 cit.
10
Type of evidence supporting ACC/AHA and ESC clinical practice guidelines for acute coronary syndrome
Clinical Research in Cardiology|2023
14 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Eric J. Topol
Scripps Institution of Oceanography
2
Robert A. Harrington
Clinical Research Institute
3
Elliott M. Antman
Brigham and Women's Hospital
4
Marc S. Sabatine
Brigham and Women's Hospital
5
Garret A. FitzGerald
California University of Pennsylvania
6
Keith A.A. Fox
University of Edinburgh
7
Salim Yusuf
Population Health Research Institute
8
Lars Wallentin
Uppsala University
9
Borja Ibáñez
Spanish National Centre for Cardiovascular Research
10
Katja Zeppenfeld
Leiden University

Papers

1
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
The Lancet|2004
12k cit.
2
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
New England Journal of Medicine|2009
11.2k cit.
3
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
European Heart Journal|2017
9.8k cit.
4
Apixaban versus Warfarin in Patients with Atrial Fibrillation
New England Journal of Medicine|2011
8.9k cit.
5
ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary
Circulation|2004
8.4k cit.
6
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
New England Journal of Medicine|2009
7.1k cit.
7
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
New England Journal of Medicine|2007
6.7k cit.
8
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine|2018
6.3k cit.
9
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
New England Journal of Medicine|2013
5.1k cit.
10
Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction
Journal of the American College of Cardiology|2000
4.8k cit.

Reagents for Antiplatelet Therapy and Cardiovascular Diseases

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 67

Vimentin (D21H3) Rabbit Monoclonal Antibody (APC Conjugate)

Cited in 5 papers
#95159$465
View Evidence →
Cell Signaling TechnologyEvidence 66

Histone H2A.X (D17A3) Rabbit Monoclonal Antibody (BSA and Azide Free)

#24533$865
View Evidence →
Cell Signaling TechnologyEvidence 64

Phospho-Stat5 (Tyr694) (D47E7) Rabbit Monoclonal Antibody (SignalFlex™ Pacific Blue™ Conjugate)

#23382$486
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 65

Sox2 (L73B4) Mouse Monoclonal Antibody

Cited in 6 papers
#4195$158,348
View Evidence →
Cell Signaling Technology

Phospho-AMPK beta1 (Ser182) Antibody

Cited in 6 papers
#4186$362
View Evidence →
Cell Signaling Technology

SIK3 Antibody

Cited in 5 papers
#39477$317
View Evidence →